Sandoz Group (OTCMKTS:SDZNY) Sets New 12-Month High – What’s Next?

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) shares reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $82.89 and last traded at $82.7550, with a volume of 3174 shares changing hands. The stock had previously closed at $81.23.

Analyst Upgrades and Downgrades

Separately, Barclays upgraded Sandoz Group to a “strong-buy” rating in a report on Monday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Sandoz Group Stock Up 1.2%

The business has a 50-day moving average of $74.17 and a 200-day moving average of $65.73. The company has a current ratio of 1.29, a quick ratio of 0.82 and a debt-to-equity ratio of 0.62.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.